[ 英語タイトル ] Prosthetic Heart Valve/ Artificial Heart Valve Market by Type (Transcatheter Heart Valve, Tissue Heart Valve, and Mechanical Heart Valve), and Region (North America, Europe, Asia-Pacific, and RoW) - Global Forecast to 2022

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH METHODOLOGY STEPS 19
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 20
2.2.1 SECONDARY RESEARCH 20
2.2.2 PRIMARY RESEARCH 21
2.2.2.1 Key industry insights 22
2.2.2.2 Key data from primary sources 23
2.2.2.3 Key insights from primary sources 24
2.3 MARKET SIZE ESTIMATION METHODOLOGY 25
2.4 RESEARCH DESIGN 29
2.5 MARKET DATA VALIDATION AND TRIANGULATION 30
2.6 ASSUMPTIONS FOR THE STUDY 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 INTRODUCTION 35
4.2 GLOBAL PROSTHETIC HEART VALVES MARKET, BY TYPE OF VALVE, 2017 VS. 2022 36
4.3 GEOGRAPHICAL SNAPSHOT OF GLOBAL PROSTHETIC HEART VALVES MARKET 37
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 Rising geriatric population and subsequent growth in prevalence of heart valve disease 40
5.2.1.2 Regulatory approvals for new and advanced prosthetic heart valves 41
5.2.1.2.1 Product approvals for Medtronic plc: 41
5.2.1.2.2 Product approvals for Edward Lifesciences Corporation: 41
5.2.1.2.3 Product approvals for Boston Scientific Corporation: 41
5.2.1.2.4 Product approvals for Livanova PLC: 42
5.2.1.2.5 Product approvals for St. Jude Medical, Inc.: 42
5.2.1.2.6 Product approvals for other companies: 42
5.2.1.3 Increasing government funding for heart valve research 43
5.2.1.4 Rising awareness about heart valve diseases 43
5.2.1.5 Favorable reimbursement scenario for prosthetic heart valves 44
5.2.2 RESTRAINTS 45
5.2.2.1 High cost of transcatheter aortic valve replacement (TAVR) procedures 45
5.2.2.2 Availability of alternative methods for treating heart valve diseases (HVD) 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Expanding indication of TAVR from only high-risk to intermediate- or low-risk patients 46
5.2.3.2 Strong product pipeline 46
5.2.3.3 Increasing investments by key players in startup companies 47
5.2.3.4 Growth potential offered by emerging countries 48
5.2.4 CHALLENGE 49
5.2.4.1 Emergence of tissue-engineered heart valves (TEHV) 49
6 GLOBAL PROSTHETIC HEART VALVE MARKET, BY TYPE OF VALVE 50
6.1 INTRODUCTION 51
6.2 TRANSCATHETER HEART VALVES 53
6.3 TISSUE HEART VALVES 57
6.4 MECHANICAL HEART VALVES 61
7 GLOBAL PROSTHETIC HEART VALVE MARKET, BY REGION 65
7.1 INTRODUCTION 66
7.2 NORTH AMERICA 67
7.2.1 U.S. 69
7.2.1.1 Rapid growth in the aging population and prevalence of valvular heart diseases 69
7.2.1.2 Rising preference for transcatheter aortic valve replacement (TAVR) 69
7.2.1.3 Favorable reimbursement scenario for prosthetic heart valves 70
7.2.1.4 Initiatives to increase awareness of valvular heart diseases (VHD) 70
7.2.1.5 Stringent regulations for new prosthetic heart valve approval 70
7.2.2 CANADA 71
7.2.2.1 Favorable reimbursement and funding 71
7.2.2.2 Rising approvals for heart valves 72
 
7.3 EUROPE 73
7.3.1 INCREASING AGING POPULATION AND VALVULAR HEART DISEASES (VHD) PREVALENCE 74
7.3.2 GROWTH IN THE NUMBER OF RESEARCH ACTIVITIES 74
7.3.3 GERMANY 76
7.3.3.1 Favorable reimbursement policies 76
7.3.4 FRANCE 77
7.3.4.1 Valve for life (VFL) initiative 77
7.3.5 U.K. 78
7.3.5.1 Establishment of specialty valve clinics 78
7.3.6 REST OF EUROPE (ROE) 79
7.3.6.1 Rising initiatives and awareness programs in Poland and Portugal 79
7.4 ASIA-PACIFIC 81
7.4.1 JAPAN 83
7.4.1.1 Rising aging population 83
7.4.1.2 Favorable reimbursement scenario 83
7.4.1.3 Dilution of regulatory stringency 84
7.4.2 CHINA 85
7.4.2.1 Rising aging population and prevalence of valvular heart diseases in china 85
7.4.2.2 Unfavorable reimbursements 85
7.4.3 INDIA 86
7.4.3.1 High patient pool for target diseases 86
7.4.3.2 State government funded insurance schemes 87
7.4.4 REST OF ASIA-PACIFIC (ROAPAC) 88
7.4.4.1 Growing medical tourism in Asian countries 88
7.5 REST OF THE WORLD 89
7.5.1 RISE IN AGING POPULATION 90
7.5.2 HIGH PREVALENCE OF HEART VALVE DISEASE IN BRAZIL 90
7.5.3 FAVORABLE MEDICAL TOURISM DESTINATION 90
8 COMPETITIVE LANDSCAPE 92
8.1 MARKET SHARE ANALYSIS (2016) 92
8.1.1 INTRODUCTION 92
8.1.2 GLOBAL TRANSCATHETER HEART VALVES MARKET SHARE, BY KEY PLAYER, 2016 92
8.1.3 GLOBAL TISSUE HEART VALVES MARKET SHARE, BY KEY PLAYER, 2016 93
8.1.4 GLOBAL MECHANICAL HEART VALVES MARKET SHARE, BY KEY PLAYER, 2016 93
8.1.5 EDWARDS LIFESCIENCES CORPORATION 94
8.1.6 MEDTRONIC PLC 95
8.1.7 ST. JUDE MEDICAL, INC. 96
 
8.2 VENDOR DIVE OVERVIEW 96
8.2.1 VANGUARDS 96
8.2.2 INNOVATOR 96
8.2.3 DYNAMIC 97
8.2.4 EMERGING 97
8.3 COMPETITIVE BENCHMARKING 98
8.3.1 ANALYSIS OF PRODUCT PORTFOLIO OF MAJOR PLAYERS IN THE PROSTHETIC HEART VALVE MARKET (18 PLAYERS) 98
8.3.2 BUSINESS STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE PROSTHETIC HEART VALVE MARKET (18 PLAYERS) 99
*Top 13 companies analysed for this study are - Edwards Lifesciences Corporation (U.S.), Medtronic plc (Ireland), St. Jude Medical, Inc. (Abbott Laboratories Company) (U.S.), Boston Scientific Corporation (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), JenaValve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil). Other players in this market include Micro Interventional Devices, Inc. (U.S.), Autotissue Berlin GmbH (Germany), Comed B.V. (Netherlands), Meril Life Sciences Pvt. Ltd. (India), Labcor Laboratórios Ltda. (Brazil), and HLT Inc. (A Bracco Group Company) (U.S.)
9 COMPANY PROFILES 100
(Overview, Products and Services, Financials, Strategy & Development)*

9.1 INTRODUCTION 100
9.2 MEDTRONIC PLC 101
9.3 EDWARDS LIFESCIENCES CORPORATION 106
9.4 BOSTON SCIENTIFIC CORPORATION 111
9.5 LIVANOVA PLC 117
9.6 ST. JUDE MEDICAL, INC. (AN ABBOTT LABORATORIES COMPANY) 122
9.7 SYMETIS SA 125
9.8 JENAVALVE TECHNOLOGY, INC. 128
9.9 CRYOLIFE, INC. 131
9.10 TTK HEALTHCARE LIMITED (A TTK GROUP COMPANY) 135
9.11 COLIBRI HEART VALVE, LLC 138
9.12 LEPU MEDICAL TECHNOLOGY CO., LTD. 141
9.13 BRAILE BIOMÉDICA 144
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
10 APPENDIX 147
10.1 DISCUSSION GUIDE 147
10.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 151
10.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 153
10.4 AVAILABLE CUSTOMIZATIONS 154
10.5 RELATED REPORTS 155
10.6 AUTHOR DETAILS 156